文献速递银屑病与炎症性皮肤病

儿童银屑病全身治疗药物的安全性

Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.
PubMed 文献 · JAMA Dermatol · 2017-01-01

该回顾性多中心研究纳入390例中重度儿童银屑病患者,评估全身药物或光疗的使用模式与不良反应。甲氨蝶呤最常见,其相关不良反应(尤其胃肠道)多于TNF抑制剂;每周6或7天补充叶酸较每周1次更能预防甲氨蝶呤所致胃肠道不良反应。

要点

  • 甲氨蝶呤相关不良反应(尤其胃肠道)比TNF抑制剂更常见
  • 每周6或7天补充叶酸比每周1次更能预防甲氨蝶呤胃肠道不良反应
  • TNF抑制剂注射部位反应常见但未导致停药,未观察到结核或恶性肿瘤

核心结论

  • TNF抑制剂药物相关不良反应少于甲氨蝶呤。
  • 每周6或7次叶酸补充比每周1次更能预防甲氨蝶呤所致胃肠道不良反应。

研究设计与样本

  • 纳入连续使用全身药物或光疗至少3个月的中重度儿童银屑病患者,共390例(女203例,男187例;诊断时平均[SD]年龄8.4[3.7]岁)。

主要发现

  • 270例(69.2%)使用甲氨蝶呤,106例(27.2%)使用生物制剂(主要为依那西普),57例(14.6%)使用阿维A,30例(7.7%)使用环孢素,19例(4.9%)使用富马酸酯,73例(18.7%)使用超过1种药物。
  • 270例使用甲氨蝶呤的儿童中,130例(48.1%)报告至少1种与甲氨蝶呤相关的不良反应,主要为胃肠道反应(67例[24.8%])。
  • 每周6天叶酸(OR 0.16;95%CI 0.06-0.41;P<.001)或每周7天叶酸(OR 0.21;95%CI 0.08-0.58;P=.003)较每周1次叶酸更能预防胃肠道不良反应,与每周总剂量无关。
  • 甲氨蝶呤相关肝转氨酶升高与肥胖相关(35/270例[13.0%]),但与叶酸方案无关;106例使用TNF抑制剂的患者中20例(18.9%)出现注射部位反应,但未导致停药。
  • 6例发生严重治疗相关不良事件(甲氨蝶呤3例、富马酸酯2例、阿达木单抗1例);未观察到结核或恶性肿瘤。

关键数值与推荐

  • 甲氨蝶呤相关不良反应、胃肠道不良反应、实验室异常或导致停药的不良反应较TNF抑制剂更常见;药物相关感染(主要为上呼吸道)较TNF抑制剂更少见。

临床怎么用

  • 儿童中重度银屑病使用甲氨蝶呤时,建议每周6或7天补充叶酸以降低胃肠道不良反应风险。
  • TNF抑制剂相关注射部位反应常见但通常不导致停药,用药期间仍需监测严重不良反应。
  • 甲氨蝶呤治疗期间应关注肥胖患者的肝转氨酶升高风险。

局限性

  • 回顾性研究设计。
  • 需要前瞻性登记研究来追踪儿童银屑病全身治疗药物的长期风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Use of systemic therapies for moderate to severe psoriasis in children is increasing, but comparative data on their use and toxicities are limited. OBJECTIVE: To assess patterns of use and relative risks of systemic agents for moderate to severe psoriasis in children. DESIGN, SETTING, AND PARTICIPANTS: A retrospective review was conducted at 20 centers in North America and Europe, and included all consecutive children with moderate to severe psoriasis who used systemic medications or phototherapy for at least 3 months from December 1, 1990, to September 16, 2014. MAIN OUTCOMES AND MEASURES: The minimal core data set included age, sex, severity of psoriasis, systemic interventions, monitoring, adverse events (AEs), and reason for discontinuation. RESULTS: For 390 children (203 girls and 187 boys; mean [SD] age at diagnosis, 8.4 [3.7] years) with psoriasis who used 1 or more systemic medications, the mean interval between diagnosis and starting systemic therapy was 3.0 years. Methotrexate was used by 270 patients (69.2%), biologic agents (primarily etanercept) by 106 (27.2%), acitretin by 57 (14.6%), cyclosporine by 30 (7.7%), fumaric acid esters by 19 (4.9%), and more than 1 medication was used by 73 (18.7%). Of 270 children taking methotrexate, 130 (48.1%) reported 1 or more AEs associated with methotrexate, primarily gastrointestinal (67 [24.8%]). Folic acid 6 days per week (odds ratio, 0.16; 95% CI, 0.06-0.41; P < .001) or 7 days per week (OR, 0.21; 95% CI, 0.08-0.58; P = .003) protected against gastrointestinal AEs more than once-weekly folic acid, regardless of the total weekly dosage. Methotrexate-associated hepatic transaminase elevations were associated with obesity (35 of 270 patients [13.0%]), but a folic acid regimen was not. Injection site reactions occurred in 20 of 106 patients (18.9%) treated with tumor necrosis factor inhibitors, but did not lead to discontinuation of treatment. Having 1 or more AEs related to medication, gastrointestinal AE, laboratory abnormality, or AE leading to discontinuation of the drug was more likely with methotrexate than tumor necrosis factor inhibitors, but having 1 or more infections related to medication (predominantly upper airway) was less likely. Six patients developed a serious treatment-related AE (methotrexate, 3; fumaric acid esters, 2; and adalimumab, 1), but methotrexate and biologic agents were taken for a mean duration that was 2-fold greater than the mean duration for cyclosporine or fumaric acid esters. No patient developed tuberculosis or a malignant neoplasm. CONCLUSIONS AND RELEVANCE: Medication-related AEs occur less often with tumor necrosis factor inhibitors than with methotrexate. Folic acid administration 6 or 7 times per week protected more against methotrexate-induced gastrointestinal AEs than did weekly administration. A prospective registry is needed to track the long-term risks of systemic agents for pediatric psoriasis.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Bronckers IMGJ, Seyger MMB, West DP, et al. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis. JAMA Dermatol. 2017. PMID: 28903160. doi:10.1001/jamadermatol.2017.3029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。